In a 75‑year‑old male with recent pneumonia treated with meropenem and now on oral moxifloxacin and cefixime, who has persistent cough, chest CT showing consolidation with bronchiectatic changes in the left upper and lower lobes and diffuse emphysematous changes, and laboratory studies demonstrating marked leukocytosis with neutrophilia, what is the likely diagnosis and recommended management?

Diagnosis: Bronchiectasis with Acute Exacerbation and Treatment Failure

This patient has bronchiectasis with an acute exacerbation that has failed initial antibiotic therapy, requiring immediate comprehensive re-evaluation, sputum culture with antibiotic susceptibilities, investigation for resistant organisms (particularly Pseudomonas aeruginosa and non-tuberculous mycobacteria), and escalation to prolonged intravenous antibiotic therapy guided by culture results. 1

Clinical Reasoning

The constellation of findings—persistent cough despite aggressive antibiotic therapy, CT-confirmed bronchiectatic changes with consolidation, and marked leukocytosis (WBC 30,000 with 90% neutrophils)—indicates a deteriorating bronchiectasis patient with ongoing severe infection. The failure to respond to meropenem (a carbapenem with broad coverage) followed by dual oral therapy (moxifloxacin plus cefixime) signals either:

• Resistant or atypical pathogens
• Inadequate antibiotic penetration
• Non-bacterial etiology (NTM, fungal)
• Underlying complications requiring different management

Immediate Diagnostic Workup

Obtain these investigations urgently:

• Sputum culture and sensitivity (including extended incubation for fastidious organisms) 1
• Acid-fast bacilli smear and mycobacterial culture (NTM testing is critical in deteriorating bronchiectasis patients who fail appropriate antibiotics) 1
• Fungal culture and galactomannan (given immunocompromised state from severe infection)
• Repeat inflammatory markers (CRP, procalcitonin if available)
• Blood cultures (given marked leukocytosis suggesting possible bacteremia)
• Serum immunoglobulins (to exclude underlying immunodeficiency contributing to treatment failure) 2

The 2025 European Respiratory Society guideline explicitly states that repeat testing for NTM should be performed when there are suggestive clinical or radiological features, particularly in those who deteriorate despite appropriate antibiotics 1. Upper lobe involvement with bronchiectasis is a classic pattern for NTM infection.

Management Algorithm

Step 1: Hospitalization and IV Antibiotics

Admit the patient immediately for intravenous antibiotic therapy. The failure of oral antibiotics (including a fluoroquinolone) indicates need for parenteral therapy with better bioavailability and broader coverage 1.

Empiric IV antibiotic regimen pending cultures:

• Consider anti-pseudomonal coverage: Piperacillin-tazobactam 4.5g IV every 6 hours OR Cefepime 2g IV every 8 hours
• Add aminoglycoside (tobramycin or amikacin) if Pseudomonas is suspected, especially given prior meropenem exposure
• Duration: Minimum 14 days IV therapy for severe bronchiectasis exacerbations 1, 3

Step 2: Adjust Based on Culture Results

• If Pseudomonas aeruginosa isolated: Continue dual anti-pseudomonal therapy based on susceptibilities for 14-21 days 1
• If NTM identified: Discontinue standard antibiotics and initiate NTM-specific multi-drug regimen (typically rifamycin + ethambutol + macrolide) 1
• If fungal infection: Initiate appropriate antifungal therapy (amphotericin B for mucormycosis, voriconazole for aspergillosis) 4

Step 3: Optimize Bronchiectasis Management

The 2025 ERS guideline emphasizes a "treatable traits" approach for deteriorating patients 1:

Airway clearance:

• Initiate twice-daily chest physiotherapy or oscillating positive expiratory pressure device
• Consider mucoactive agents (hypertonic saline 7% nebulized twice daily)

Bronchodilators:

• Trial of inhaled bronchodilators given coexisting emphysema (albuterol/ipratropium)

Anti-inflammatory therapy:

• Consider macrolide therapy (azithromycin 250-500mg three times weekly) AFTER ruling out NTM, as macrolide monotherapy can induce NTM resistance 1, 3

Step 4: Specialist Referral

Refer to pulmonologist with bronchiectasis expertise 1. The guideline explicitly states that deteriorating patients not already under specialist care should be referred to a respiratory clinic with bronchiectasis expertise.

Critical Pitfalls to Avoid

1. Do not continue the current oral antibiotic regimen—this represents treatment failure and risks further deterioration and antibiotic resistance development

2. Do not start macrolide therapy before excluding NTM—macrolide monotherapy against NTM induces resistance and compromises future treatment 1

3. Do not assume this is simple bacterial pneumonia—the bronchiectatic changes, upper lobe predominance, and treatment failure mandate investigation for atypical organisms

4. Do not discharge on oral antibiotics—the marked leukocytosis (WBC 30,000) and treatment failure indicate severe infection requiring IV therapy

5. Avoid moxifloxacin continuation—rare cases of drug-induced pneumonia from moxifloxacin exist, and fluoroquinolone failure suggests resistant organisms 5

Prognosis and Follow-up

The marked neutrophilia (90% PMN) reflects severe ongoing neutrophilic inflammation, which drives bronchiectasis progression 6. After acute management:

• Repeat chest CT in 6-8 weeks to assess response and identify any progression 1
• Pulmonary function testing to establish baseline and assess severity
• Consider long-term suppressive antibiotic therapy if recurrent exacerbations (≥3 per year) after acute phase resolves 1, 3

The combination of age (75 years), underlying emphysema, and severe bronchiectasis places this patient at high risk for mortality without aggressive intervention and ongoing specialist management.